Users rave about this scooter's impressive 80 km range and smooth performance. Highly praised for its safety features and convenient charging, though it may lack advanced smart features. Three Gears: ...

Christopher Young: Welcome everyone and thank you for joining us. It's great to join you on my first earnings conference call as President and CEO of Vertex. Our financial results for the fourth ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Thursday afternoon. Here’s what you need to know. Vertex Pharmaceuticals met analysts’ revenue expectations last ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

This is a Quick Blender tutorial on use Vertex Weight Proximity, Wireframe and Subdivision Surface Modifier in Blender 2.9 Hope it is useful to you Thanks for watching Enormous freshwater reservoir ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy. Vertex clocked 11% growth ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Vertex ( (VERX)) has shared an update. On ...

Vertex Pharma ceuticals CEO Reshma Kewalramani bought a big chunk of the biotech’s stock earlier this month. The move, her first open-market purchase in years, appears to be a show of confidence in ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...